Bill Gates (Leon Neal/Pool via AP Images)
Vir expands partnership with Gates Foundation, adding $50M for HIV and malaria antibody research initiative
Just two days after the US bought 600,000 more doses of Vir and GSK’s Covid-19 antibody sotrovimab to guard against Omicron, Vir Biotechnology announced a partnership expansion with the Bill and Melinda Gates Foundation for its T-cell vaccine program.
The partnership had been in place for a few years with Vir’s T-cell vaccine program targeting TB and HIV. The foundation is putting up $50 million — $10 million in the form of a grant and the rest in an equity investment.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters